The FDA approved a targeted therapy entrectinib (Rozlytrek) for either NTRK+ solid tumors or ROS1+ patients with metastatic non-small cell lung cancer (NSCLC).

This approval broadens the treatment options for patients with solid tumors that test positive for the NTRK genetic alteration whose disease continues to progress on standard treatment therapies. The NTRK genetic alteration is not exclusive to lung cancer and applies to any solid cancer tumors where NTRK is present.

As for patients with metastatic NSCLC who test positive for the ROS1 genetic alteration, this latest approval means ROS1 patients now have four targeted therapy treatment options. Read more here.